Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

NCT03916679 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT03916679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03916679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 20, 2019
Completion date
April 20, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer